

(Authority: Government in the Sunshine Act, 5 U.S.C. 552b)

Vicktoria J. Allen,

Deputy Secretary of the Commission.

[FR Doc. 2025–09415 Filed 5–21–25; 11:15 am]

BILLING CODE 6715–01–P

FEDERAL RESERVE SYSTEM

Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities

Correction

In the **Federal Register** of May 9, 2025, FR Doc. 2025–08188, the notice “Notice of Proposals to Engage in or to Acquire Companies Engaged in Permissible Nonbanking Activities” by the Federal Reserve Bank of San Francisco, *Lewis & Clark Bancorp, Oregon City, Oregon*; is corrected to read “to acquire additional interests in iCashe, Inc., Portland, Oregon, and thereby continue to indirectly engage in trust company functions, printing and selling MICR-encoded items, and data processing, pursuant to sections 225.28(b)(5), 225.28(b)(10)(ii), and 225.28(b)(14), respectively, all of the Board’s Regulation Y”, and that the company listed applied to the Board for approval, pursuant to section 4 of the Bank Holding Company Act (12 U.S.C. 1843) and Regulation Y (12 CFR part 225) to engage de novo, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States. The comment period continues to end on May 27, 2025. Interested persons may continue to view the notice and submit comments as provided in 90 FR 19717 (May 9, 2025) no later than May 27, 2025.

Board of Governors of the Federal Reserve System.

Erin Cayce,

Assistant Secretary of the Board.

[FR Doc. 2025–09342 Filed 5–22–25; 8:45 am]

BILLING CODE P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than June 9, 2025.

A. Federal Reserve Bank of Minneapolis (Mark Nagle, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55480–0291. Comments can also be sent electronically to MA@mpls.frb.org:

1. *Nancy Ferche, individually, and as trustee of the Robert Ferche Revocable Trust, as amended, (the “Ferche Trust”) and Marital Trust governed by the Ferche Trust agreement, all of St. Stephen, Minnesota*; to acquire voting shares of St. Joseph Bancshares Acquisitions, Inc. (“Company”), and thereby indirectly acquire voting shares of Sentry Bank, both of Saint Joseph, Minnesota, and Sherburne State Bank, Becker, Minnesota (the “Banks”).

Additionally, Kimberly M. Juelke Revocable Trust, with Kimberly Juelke as trustee, both of Little Falls, Minnesota; Jason R. Ferche 2006 Revocable Trust, as amended, with Jason Ferche as trustee, both of Rice, Minnesota; Tamara L. Layne Revocable Trust, with Tamara O’Hara (formerly known as Tamara L. Layne) as trustee, both of Sartell, Minnesota; and Cheryl A. Lumley Revocable Trust, as amended, with Cheryl Ferche (formerly known as Cheryl A. Lumley) as trustee, both of Sartell, Minnesota; to join the Ferche Family Control Group, a group acting in concert, to acquire voting shares of the Company, and thereby indirectly acquire voting shares of the Banks.

Board of Governors of the Federal Reserve System.

Erin Cayce,

Assistant Secretary of the Board.

[FR Doc. 2025–09344 Filed 5–22–25; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Emergency Medical Services for Children Innovation and Improvement Center

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Announcing period of performance extension with funding for Emergency Medical Services for Children Innovation and Improvement Center (EIIC) Award recipient.

SUMMARY: HRSA plans to provide additional funds to the University of Texas at Austin, Texas, the current EIIC Program recipient, to extend the recipient’s current period of performance by 12 months. This extension is necessary to support continuity of operations that facilitate pediatric readiness activities in hospital emergency departments (ED) and prehospital emergency medical services (EMS) agencies throughout the country. The current performance period ends June 30, 2025.

FOR FURTHER INFORMATION CONTACT: Sara B Kinsman, M.D., Ph. D., Director, Division of Child, Adolescence, and Family Health, at SKinsman@hrsa.gov and 240–475–3712.

SUPPLEMENTARY INFORMATION:

Intended Recipient(s) of the Award: University of Texas at Austin, Texas.

Amount of Competitive Award(s): One award for \$2,500,000.

Project Period: July 1, 2025–June 30, 2026.

Assistance Listing (Catalog of Federal Domestic Assistance) Number: 93.127.

Award Instrument: Cooperative Agreement.

Authority: 42 U.S.C. 300w–9 (Public Health Service Act, title XIX, sec. 1910).

Purpose/Justification: The Emergency Medical Services for Children (EMSC) program funds demonstration projects to expand and improve emergency medical services for children who need treatment for trauma or critical care. EIIC provides technical support to states and jurisdictions to achieve the EMSC program's mandate by increasing pediatric readiness in hospital EDs and prehospital EMS agencies to improve outcomes for children. EIIC supports demonstration projects to implement evidence-based clinical guidelines and establish evidence-based training for emergency care practitioners in hospital EDs and prehospital EMS agencies in underserved communities. EIIC was established in 2016 through a 4-year cooperative agreement. HRSA's Maternal and Child Health Bureau re-competed the program in 2020 for another 4 years and extended the program for an additional year in fiscal year 2024 to support the first comprehensive national assessment of prehospital agencies and continue quality improvement activities to increase pediatric readiness. The current budget period ends on June 30, 2025. Renewal of this grant will allow EIIC to continue to advance pediatric readiness nationally during this upcoming extension period in both prehospital EMS and hospital emergency departments through the dissemination of data. HRSA intends to re-compete this program prior to the end of the 12-month extension period. HRSA will award \$2,500,000 to the existing EIIC Program award recipient to continue operations as outlined in HRSA–20–037 Notice of Funding Opportunity.

Thomas J. Engels,
Administrator.

[FR Doc. 2025–09294 Filed 5–22–25; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

National Vaccine Injury Compensation Program; List of Petitions Received

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: HRSA is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (the Program), as required by the Public Health Service (PHS) Act, as amended. While the Secretary of HHS is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.

FOR FURTHER INFORMATION CONTACT: For information about requirements for filing petitions, and the Program in general, contact Lisa L. Reyes, Clerk of Court, United States Court of Federal Claims, 717 Madison Place NW, Washington, DC 20005, (202) 357–6400. For information on HRSA's role in the Program, contact the Director, Division of Injury Compensation Programs, 5600 Fishers Lane, Room 8W–25A, Rockville, Maryland 20857; 1–800–338–2382, or visit our website at: <https://www.hrsa.gov/vaccine-compensation>.

SUPPLEMENTARY INFORMATION: The Program provides a system of no-fault compensation for certain individuals who have been injured by specified childhood vaccines. Subtitle 2 of Title XXI of the PHS Act, 42 U.S.C. 300aa–10 *et seq.*, provides that those seeking compensation are to file a petition with the United States Court of Federal Claims and to serve a copy of the petition to the Secretary of HHS, who is named as the respondent in each proceeding. The Secretary has delegated this responsibility under the Program to HRSA. The Court is directed by statute to appoint special masters who take evidence, conduct hearings as appropriate, and make initial decisions as to eligibility for, and amount of, compensation.

A petition may be filed with respect to injuries, disabilities, illnesses, conditions, and deaths resulting from vaccines described in the Vaccine Injury Table (the Table) set forth at 42 CFR 100.3. This Table lists for each covered childhood vaccine the conditions that may lead to compensation and, for each

condition, the time period for occurrence of the first symptom or manifestation of onset or of significant aggravation after vaccine administration. Compensation may also be awarded for conditions not listed in the Table and for conditions that are manifested outside the time periods specified in the Table, but only if the petitioner shows that the condition was caused by one of the listed vaccines.

Section 2112(b)(2) of the PHS Act, 42 U.S.C. 300aa–12(b)(2), requires that “[w]ithin 30 days after the Secretary receives service of any petition filed under section 2111 the Secretary shall publish notice of such petition in the **Federal Register**.” Set forth below is a list of petitions received by HRSA on April 1, 2025, through April 30, 2025. This list provides the name of the petitioner, city, and state of vaccination (if unknown then the city and state of the person or attorney filing the claim), and case number. In cases where the Court has redacted the name of a petitioner and/or the case number, the list reflects such redaction.

Section 2112(b)(2) also provides that the special master “shall afford all interested persons an opportunity to submit relevant, written information” relating to the following:

1. The existence of evidence “that there is not a preponderance of the evidence that the illness, disability, injury, condition, or death described in the petition is due to factors unrelated to the administration of the vaccine described in the petition,” and

2. Any allegation in a petition that the petitioner either:

a. “[S]ustained, or had significantly aggravated, any illness, disability, injury, or condition not set forth in the Vaccine Injury Table but which was caused by” one of the vaccines referred to in the Table, or

b. “[S]ustained, or had significantly aggravated, any illness, disability, injury, or condition set forth in the Vaccine Injury Table the first symptom or manifestation of the onset or significant aggravation of which did not occur within the time period set forth in the Table but which was caused by a vaccine” referred to in the Table.

In accordance with section 2112(b)(2), all interested persons may submit written information relevant to the issues described above in the case of the petitions listed below. Any person choosing to do so should file an original and three (3) copies of the information with the Clerk of the United States Court of Federal Claims at the address listed above (under the heading “For Further Information Contact”), with a copy to HRSA addressed to Director,